• Decision-making in localized prostate cancer: Quality of life issues
• New events in the treatment of prostate cancer at Cornell
• What's New - Overview

Recent initiation of a trial to treat men with advanced prostate cancer has occurred at Cornell using monoclonal antibodies to cancer cells. An antibody (sometimes referred to as a "magic bullet") to a cell surface protein called PSMA (Prostate-specific membrane antigen) is being used with a radioactive tag in a new trial at Cornell to treat men with prostate cancer that is not treatable with routine means. This antibody, initially formed using mouse elements, has been "humanized" so that it will not be rejected by the human body and linked to Yttrium, a highly effective radioactive material. The agent is injected into the body, where it will tend to seek out and kill sites of prostate cancer throughout the body. This trial is performed with Institutional Review Board approval at Cornell and Neil H. Bander, M.D. is the Principal Investigator. To learn more about enrollment, please call Dr.. Bander or Dr. David Nanus.

Many men with prostate cancer will also have hernias present. A hernia can trap intestines, which may then be more likely to be affected by radiation and increases the risk of complications (radiation injury to bowel.) For men who are undergoing radical prostatectomy and have hernias, a new technique has been described by Cornell Urologists to simultaneously provide repair of the hernia and removal of the prostate. This approach has been described in recent publications by Drs. Peter Schlegel and Darracott Vaughan. Please contact the office of Drs. Schlegel or Vaughan for information on how this treatment could be helpful for you.